Physician profile
Bruce Lobar
NPI 1679534853
$228.64
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2021: $12.10 · 2022: $110.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $94.76 | 2022 | |
| Avanir Pharmaceuticals, INC. | $45.16 | 2019 | |
| Novo Nordisk INC | $27.59 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $21.47 | 2019 | |
| Csl Behring | $15.97 | 2019 | |
| Ucb, INC. | $12.76 | 2019 | |
| Amgen INC. | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Lobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.